Enhanced survivin siRNA delivery using cationic liposome incorporating fatty acid-modified polyethylenimine

Abstract

We described a novel approach for survivin siRNA cellular delivery via a cationic liposome incorporating fatty acid-modified polyethylenimine. A linoleic acid derivative of branched polyethylenimine(PEI, M _w=25 kDa), PEI-LA, was synthesized and incorporated into the liposome. The properties of the liposome, cytotoxicity, cellular uptake of cancer cells for survivin siRNA, survivin protein downregulation levels were investigated. PEI-modified liposome showed a lower cytotoxicity and delivered survivin siRNA into HeLa cells and A549 cells efficiently compared with PEI-25kDa.

Keywords

Polyethylenimine / siRNA / Survivin / Cationic liposome / Cancer

References

[1] Wang X. M., Yu B., Ren W., Mo X. K., Zhou C. G., He H. Y., Jia H. L., Wang L., Jacob S. T., Lee R. J., Ghoshal K., Lee L. J. Journal of Controlled Release, 2013, 172(3): 690.

[2] Yu B., Wang X. M., Zhou C. G., Teng L. S., Ren W., Yang Z. G., Shih C. H., Wang T. Y., Lee R. J., Tang S. Q., Lee L. J. Pharmaceutical Research, 2014, 31(10): 2685.

[3] Han S. E., Kang H., Shim G. Y., Suh M. S., Kim S. J., Kim J. S., Oh Y. K. International Journal of Pharmaceutics, 2008, 353(1/2): 260.

[4] Ganas C., Weiss A., Nazarenus M., Rosler S., Kissel T., Gil P. R., Parak W. J. Journal of Controlled Release, 2014, 196: 132.

[5] Darvishi M. H., Nomani A., Amini M., Shokrgozar M. A., Dinarvand R. International Journal of Pharmaceutics, 2013, 456(2): 408.

[6] Uchida H., Tanaka T., Sasaki K., Kato K., Dehari H., Ito Y., Kobune M., Miyagishi M., Taira K., Tahara H., Hamada H. Molecular Therapy, 2004, 10(1): 162.

[7] Fuessel S., Herrmann J., Ning S. L., Kotzsch M., Kraemer K., Schmidt U., Hakenberg O. W., Wirth M. P., Meye A. Cancer Letters, 2006, 232(2): 243.

[8] Kami K., Doi R., Koizumi M., Toyoda E., Mori T., Ito D., Fujimoto K., Wada M., Miyatake S. I., Imamura M. Surgery, 2004, 136(2): 443.

[9] Pennati M., Colella G., Folini M., Citti L., Daidone M. G., Zaffaroni N. Journal of Clinical Investigation, 2002, 109(2): 285.

[10] Choi K. S., Lee T. H., Jung M. H. Cancer Gene Therapy, 2003, 10(2): 87.

[11] Ma Z., Li J., He F. T., Wilson A., Pitt B., Li S. Biochemical and Biophysical Research Communications, 2005, 330(3): 755.

[12] Sioud M., Sorensen D. R. Biochemical and Biophysical Research Communications, 2003, 312(4): 1220.

[13] Zhou C. G., Zhang Y., Yu B., Phelps M. A., Lee L. J., Lee R. J. Nanomedicine-nanotechnology Biology and Medicine, 2013, 9(4): 504.

[14] Spagnou S., Miller A. D., Keller M. Biochemistry, 2004, 43(42): 13348.

[15] Zhang C. L., Tang N., Liu X. J., Liang W., Xu W., Torchilin V. P. Journal of Controlled Release, 2006, 112(2): 229.

[16] Yang Z. Z., Li J. Q., Wang Z. Z., Dong D. W., Qi X. R. Biomaterials, 2014, 35(19): 5226.

[17] Kim H. K., Davaa E., Myung C. S., Park J. S. International Journal of Pharmaceutics, 2010, 392(1/2): 141.

[18] Shim G., Han S. E., Yu Y. H., Lee S., Lee H. Y., Kim K., Kwon I. C., Park T. G., Kim Y. B., Choi Y. S., Kim C. W., Oh Y. K. Journal of Controlled Release, 2011, 155(1): 60.

[19] Teng L. S., Xie J., Teng L. R., Lee R. J. Anticancer Research, 2012, 32(4): 1267.

[20] Hsu C. Y. M., Uludag H. Biomaterials, 2012, 33(31): 7834.

[21] Bahadur K. C. R., Uludag H. Journal of Biomaterials Science, Polymer Edition, 2011, 22(7): 873.

[22] Xie J., Teng L., Yang Z., Zhou C., Liu Y., Yung B. C., Lee R. J. BioMed Research International, 2013, 2013: 710502.